Table 1 Demographics and clinical characteristics of eligible patients with stage II CRC
Characteristics | All patients | Training group | Validation group | p value |
|---|---|---|---|---|
N = 1708 | N = 1084 | N = 624 | ||
Gender, n (%) | 0.157 | |||
Female | 645 (37.8) | 423 (39.0) | 222 (35.6) | |
Male | 1063 (62.2) | 661 (61.0) | 402 (64.4) | |
Age, n (%) | 0.883 | |||
< 60 | 806 (47.2) | 513 (47.3) | 293 (47.0) | |
≥ 60 | 902 (52.8) | 571 (52.7) | 331 (53.0) | |
Pre-CEA, n (%) | 0.226 | |||
Negative | 1121 (65.6) | 700 (64.6) | 421 (67.5) | |
Positive | 587 (34.4) | 384 (35.4) | 203 (32.5) | |
Family history, n (%) | 0.480 | |||
No | 1171 (68.6) | 732 (67.5) | 439 (70.4) | |
Yes | 429 (25.1) | 281 (26.0) | 148 (23.7) | |
Unknown | 108 (6.3) | 71 (6.5) | 37 (5.9) | |
Adjuvant CT, n (%) | 0.318 | |||
No | 476 (27.9) | 311 (28.7) | 165 (26.4) | |
Yes | 1232 (72.1) | 773 (71.3) | 459 (73.6) | |
Tumor site, n (%) | 0.414 | |||
Left | 1206 (70.6) | 758 (69.9) | 448 (71.8) | |
Right | 502 (29.4) | 326 (30.1) | 176 (28.2) | |
T stage, n (%) | 0.219 | |||
T3 | 1124 (65.8) | 697 (64.3) | 427 (68.4) | |
T4a | 550 (32.2) | 365 (33.7) | 185 (29.7) | |
T4b | 34 (2.0) | 22 (2.0) | 12 (1.9) | |
Histological type, n (%) | 0.585 | |||
Adenocarcinoma | 1386 (81.1) | 877 (80.9) | 509 (81.6) | |
Mucinous adenocarcinoma | 316 (18.5) | 202 (18.6) | 114 (18.3) | |
Signet-ring cell carcinoma | 6 (0.4) | 5 (0.5) | 1 (0.1) | |
Histological differentiation, n (%) | 0.840 | |||
Well | 143 (8.4) | 94 (8.7) | 49 (7.8) | |
Moderate | 1349 (79.0) | 853 (78.7) | 496 (79.5) | |
Poor | 216 (12.6) | 137 (12.6) | 79 (12.7) | |
Tumor size, n (%) | 0.421 | |||
< 4 | 614 (35.9) | 382 (35.2) | 232 (37.2) | |
≥ 4 | 1094 (64.1) | 702 (64.8) | 392 (62.8) | |
LNH, n (%) | 0.495 | |||
< 12 | 296 (17.3) | 193 (17.8) | 103 (16.5) | |
≥ 12 | 1412 (82.7) | 891 (82.2) | 521 (83.5) | |
Lymphovascular invasion, n (%) | 0.943 | |||
Negative | 1534 (89.8) | 974 (89.9) | 560 (89.7) | |
Positive | 174 (10.2) | 110 (10.1) | 64 (10.3) | |
Perineural invasion, n (%) | 0.351 | |||
Negative | 1463 (85.7) | 922 (85.1) | 541 (86.7) | |
Positive | 245 (14.3) | 162 (14.9) | 83 (13.3) | |
CRM, n (%) | 0.429 | |||
Negative | 1688 (98.8) | 1073 (99.0) | 615 (98.6) | |
Positive | 20 (1.2) | 11 (1.0) | 9 (1.4) | |
MMR status, n (%) | 0.602 | |||
dMMR | 456 (26.7) | 294 (27.1) | 162 (26.0) | |
pMMR | 1252 (73.3) | 790 (72.9) | 462 (74.0) | |
Tumor stage, n (%) | 0.219 | |||
Stage IIA | 1124 (65.8) | 697 (64.3) | 427 (68.4) | |
Stage IIB | 550 (32.2) | 365 (33.7) | 185 (29.7) | |
Stage IIC | 34 (2.0) | 22 (2.0) | 12 (1.9) |